Search - tctmd.com

Displaying 841 - 860 of 3616

Sort: Relevancy | Date

Presentation TCT 2015

Cerebral Embolic Protection Devices: Sentinel Dual Filter Device Update of US Pivotal Clinical Trial

Presenter: Susheel Kodali, Axel Linke

October 14, 2015

Presentation TCT 2015

CE-Approved or EU Studies: JenaValve Technology Review and Clinical Update (JUPITER Trials)

Presenter: Martin B. Leon, Nicolo Piazza, Hendrik Treede

October 14, 2015

Presentation TCT 2015

Controversial Viewpoints: Clinical Trial Designs for Transcatheter Repair/Replacement of Functional MR COUNTERPOINT: The COAPT Bar Is Set Too High and Alternative Trial Designs Are Needed!

Presenter: John C Laschinger, Michael J. Mack, Neil E. Moat

October 14, 2015

Presentation TCT 2015

New Randomized Trial Data (1-Year Outcomes): ABSORB III (TCT Late-Breaking Clinical Trial Results and Beyond)

Presenter: Stephen G. Ellis, Patrick W. Serruys, Dean J. Kereiakes

October 14, 2015

Presentation TCT 2015

Controversial Viewpoints: Clinical Trial Designs for Transcatheter Repair/Replacement of Functional MR POINT: Defending MVARC and COAPT as the Clear Path to Approval

Presenter: John C Laschinger, Michael J. Mack

October 14, 2015

Presentation TCT 2015

CE-Approved or EU Studies: ACURATE Technical Specifications and Clinical Trial Results (CE Study and Other EU Results)

Presenter: Martin B. Leon, Nicolo Piazza, Helge Möllmann

October 14, 2015

Presentation TCT 2015

New Randomized Trial Data (1-Year Outcomes): ABSORB China (TCT Late-Breaking Clinical Trial Results and Beyond)

Presenter: Stephen G. Ellis, Patrick W. Serruys, Run-Lin Gao

October 14, 2015

Presentation TCT 2015

FDA-Approved or US IDE Studies: PORTICO Technical Specifications and Clinical Trial Results (CE Study and US Trial Updates)

Presenter: Ariel Finkelstein, Ganesh Manoharan, Raj Makkar

October 14, 2015

Presentation TCT 2015

PRIMA Trial: Lessons Learned

Presenter: David Hildick-Smith, Jonathan M. Tobis

October 14, 2015

Presentation TCT 2015

Reversal Agents for Factor Xa Inhibitors

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Presentation TCT 2015

PREMIUM Trial: Lessons Learned

Presenter: David Hildick-Smith, Jonathan M. Tobis

October 14, 2015

Presentation TCT 2015

FDA-Approved or US IDE Studies: DIRECT FLOW Technical Specifications and Clinical Trial Results (DISCOVER and SALUS Clinical Studies)

Presenter: Ariel Finkelstein, Ganesh Manoharan, Isaac George

October 14, 2015

Presentation TCT 2015

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe, Manesh R. Patel

October 14, 2015

Presentation TCT 2015

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Presentation TCT 2015

FDA-Approved or US IDE Studies: SAPIEN 3 - Technical Specifications and Clinical Trial Results (CE Studies and PARTNER II S3HR and S3i)

Presenter: Ariel Finkelstein, Ganesh Manoharan, Susheel Kodali

October 14, 2015

Presentation TCT 2015

FDA-Approved or US IDE Studies: EVOLUT R Technical Specifications and Clinical Trial Results (CE Study and Available US Results)

Presenter: Ariel Finkelstein, Ganesh Manoharan, Jeffrey J. Popma

October 14, 2015

Presentation TCT 2015

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

Presenter: Lisa K. Jennings, Matthew T. Roe, Pascal Vranckx

October 14, 2015

Presentation TCT 2015

MASTER: A Prospective Randomized Trial of a Bioabsorbable-Polymer Biolimus-Eluting Stent Versus Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction

Presenter: Bernard J. Gersh, Thomas F. Luscher, Cesar Moris

October 14, 2015

Presentation TCT 2015

TWENTE: A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Five-Year Outcomes

Presenter: Bernard J. Gersh, Thomas F. Luscher, Clemens von Birgelen

October 14, 2015

Presentation TCT 2015

MISTRAL C: A Prospective Randomized Trial of Embolic Protection During Transcatheter Aortic Valve Replacement

Presenter: Bernard J. Gersh, Thomas F. Luscher, Nicolas M. Van Mieghem

October 14, 2015

Advertisement

Cerebral Embolic Protection Devices: Sentinel Dual Filter Device Update of US Pivotal Clinical Trial

CE-Approved or EU Studies: JenaValve Technology Review and Clinical Update (JUPITER Trials)

Controversial Viewpoints: Clinical Trial Designs for Transcatheter Repair/Replacement of Functional MR COUNTERPOINT: The COAPT Bar Is Set Too High and Alternative Trial Designs Are Needed!

New Randomized Trial Data (1-Year Outcomes): ABSORB III (TCT Late-Breaking Clinical Trial Results and Beyond)

Controversial Viewpoints: Clinical Trial Designs for Transcatheter Repair/Replacement of Functional MR POINT: Defending MVARC and COAPT as the Clear Path to Approval

CE-Approved or EU Studies: ACURATE Technical Specifications and Clinical Trial Results (CE Study and Other EU Results)

New Randomized Trial Data (1-Year Outcomes): ABSORB China (TCT Late-Breaking Clinical Trial Results and Beyond)

FDA-Approved or US IDE Studies: PORTICO Technical Specifications and Clinical Trial Results (CE Study and US Trial Updates)

PRIMA Trial: Lessons Learned

Reversal Agents for Factor Xa Inhibitors

PREMIUM Trial: Lessons Learned

FDA-Approved or US IDE Studies: DIRECT FLOW Technical Specifications and Clinical Trial Results (DISCOVER and SALUS Clinical Studies)

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

FDA-Approved or US IDE Studies: SAPIEN 3 - Technical Specifications and Clinical Trial Results (CE Studies and PARTNER II S3HR and S3i)

FDA-Approved or US IDE Studies: EVOLUT R Technical Specifications and Clinical Trial Results (CE Study and Available US Results)

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

MASTER: A Prospective Randomized Trial of a Bioabsorbable-Polymer Biolimus-Eluting Stent Versus Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction

TWENTE: A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Five-Year Outcomes

MISTRAL C: A Prospective Randomized Trial of Embolic Protection During Transcatheter Aortic Valve Replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content